Dr. Mark S. Litwin, MD

Dr. Litwin practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Litwin's NPI, 1356369946, was assigned on July 18, 2006. Dr. Litwin graduated from Emory School of Medicine in 1985. Dr. Litwin holds California license G70266.

Dr. Litwin's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Litwin's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Litwin is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Urology. Dmand AI also links Dr. Litwin to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Litwin practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Litwin's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Litwin is board certified in urology by the American Board of Urology. Dmand AI has Dr. Litwin's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists bladder disease, enlarged prostate, erectile dysfunction, kidney cysts, kidney stone disease, prostate cancer, prostate surgery and urinary endoscopy among the conditions Dr. Litwin treats.

CMS data shows 222 Medicare services from Dr. Litwin across 7 procedure codes in 2024, for 140 Medicare patients. Medicare paid $29,083 for them. Every service was in an office.

CMS counts 140 Medicare patients who saw Dr. Litwin in 2024. The largest group is 65 to 74, with 62 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Litwin's median patient age at 64, with 15% women.

In 2024, Dr. Litwin wrote 63 Medicare Part D claims for 24 patients. 100% of them were for generic drugs. CMS names the drug for 19 of them, across 1 drug with 11 or more claims each, at $356 in total drug cost. In 2023, CMS named 36 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Litwin for performance year 2024, reported as part of a group. Dr. Litwin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Litwin as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 39 papers to Dr. Litwin, published from 2013 to 2025. 2025 was the busiest year, with 3. The most frequent topics are Prostatic Neoplasms. Dr. Litwin's most frequent co-authors are Karim Chamie, MD, Jonathan Bergman, MD and Marcia McGory Russell, MD.

Dmand AI links Dr. Litwin to 1 clinical trial. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 21 general payments to Dr. Litwin from 4 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 64% of the total. Rochester Medical Corporation paid the most, $203.

Dmand AI lists 23 awards for Dr. Litwin, most recently Alpha Omega Alpha in 2013.

Dr. Litwin graduated from Emory School of Medicine in 1985. Dr. Litwin is a member of AOA, American Association of Genitourinary Surgeons, ACS, AUA and Clinical Society of Genitourinary Surgeons.

Dr. Litwin is in network with 8 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.